Laddar...
Bispecific T cell engager (BiTE(®)) antibody constructs can mediate bystander tumor cell killing
For targets that are homogenously expressed, such as CD19 on cells of the B lymphocyte lineage, immunotherapies can be highly effective. Targeting CD19 with blinatumomab, a CD19/CD3 bispecific antibody construct (BiTE(®)), or with chimeric antigen receptor T cells (CAR-T) has shown great promise for...
Sparad:
| I publikationen: | PLoS One |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
Public Library of Science
2017
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5570333/ https://ncbi.nlm.nih.gov/pubmed/28837681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0183390 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|